OSE Immunotherapeutics Reports 2025 First Half Financial Results

OSE Immunotherapeutics disclosed its financial outcomes for the first half of 2025, highlighting significant changes from the previous year. The company's operating income decreased sharply to €1.4 million compared to €82.6 million in 2024, primarily due to the deferred recognition of a licensing agreement payment and diminished revenue sources.

Research and development expenses increased by 6.7%, reaching €14.8 million, as the company continues pushing forward with its projects, including the Phase 3 trial of Tedopi® - Artemia. Meanwhile, general administrative costs slightly rose to €4.5 million.

As a consequence, OSE reported an operating loss of €15.8 million, a significant swing from the €63.3 million profit in the same period last year. The net cash flow scenario also shifted dramatically, with a notable decline in cash from operating activities to a negative €19.2 million.

Despite challenges, OSE's cash assets stand at €25.4 million, with a total cash position of €41.6 million. The company is reviewing strategic options to extend liquidity beyond Q4 2026, targeting potential partnerships and equity financing to sustain operations.